Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
Rhea-AI Summary
Silo Pharma (NASDAQ: SILO) highlighted its lead intranasal PTSD candidate, SPC-15, and said it is positioned to benefit from renewed federal focus on psychedelic-based therapies following an April 18, 2026 executive order directing agencies to accelerate research.
SPC-15 is a 5-HT4 receptor agonist delivered intranasally via a nose-to-brain device, advanced under a 505(b)(2) regulatory pathway, backed by Columbia University-licensed IP, and preparing for IND engagement with the FDA.
Positive
- None.
Negative
- None.
News Market Reaction – SILO
On the day this news was published, SILO gained 29.34%, reflecting a significant positive market reaction. Argus tracked a peak move of +51.5% during that session. Argus tracked a trough of -18.5% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $8.38M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SILO was up 1.18% pre-release while momentum peers NCNA, ALZN and ARTL showed declines of about -5% to -7%. Broader sector peers in biotechnology were mixed, suggesting this policy-aligned PTSD update was more stock-specific than part of a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | European patent allowance | Positive | +49.0% | European allowance expanding SPC-15 prophylactic PTSD IP protection. |
| Feb 23 | Share buyback authorization | Positive | +24.0% | Board-approved repurchase program of up to $1,000,000 in common stock. |
| Feb 18 | Japan patent allowance | Positive | -3.2% | Notice of Allowance in Japan for SPC-15 intranasal PTSD patent. |
| Dec 30 | Phase 1 LOI | Positive | +4.7% | LOI with Allucent to support two Phase 1 SPC-15 SAD and MAD studies. |
| Nov 17 | Allucent partnership | Positive | -1.1% | Partnership with Allucent for planned 2026 FDA IND preparation for SPC-15. |
Recent positive corporate or IP milestones often aligned with strong upside moves, but select patent and partnership updates have seen modest negative reactions, indicating inconsistent follow-through on good news.
Over the last six months, Silo Pharma has repeatedly advanced SPC-15 and its PTSD franchise. A European patent allowance on Apr 06, 2026 drove a 49.02% move, while a $1,000,000 share repurchase authorization on Feb 23, 2026 coincided with a 24% gain. Earlier, Japan patent progress, an LOI with Allucent for Phase 1 work, and partnering for an FDA IND submission highlighted the clinical path for SPC-15, though reactions were mixed, with both small gains and modest declines.
Market Pulse Summary
The stock surged +29.3% in the session following this news. A strong positive reaction aligns with Silo Pharma’s history of sharp moves on SPC-15 milestones, such as prior patent and program updates. The policy backdrop around psychedelic-based PTSD treatment could have amplified interest. However, prior reactions have not always been sustained, and recent warrant-related registrations and equity issuances in filings highlight ongoing financing dynamics that could influence future trading behavior.
Key Terms
post-traumatic stress disorder medical
ptsd medical
505(b)(2) regulatory pathway regulatory
intranasal medical
serotonin 4 (5-HT4) receptor agonist medical
cns medical
nose-to-brain delivery medical
AI-generated analysis. Not financial advice.
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies
SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today highlighted the strength and strategic positioning of its pipeline in response to increasing national attention and policy discussion surrounding psychedelic-based treatments for mental health disorders.
Recent national media coverage has underscored growing momentum at the federal level to evaluate reforms related to psychedelic compounds for medical use—particularly in areas such as post-traumatic stress disorder (PTSD), depression, and anxiety. On Saturday, April 18, 2026, President Trump signed an executive order directing multiple U.S. government agencies to accelerate research into psychedelic therapies and patient access.
Silo Pharma’s lead program, SPC-15, is an intranasal prophylactic treatment targeting PTSD, designed to leverage rapid nose-to-brain delivery for enhanced therapeutic effect and patient compliance. The program is being advanced under a 505(b)(2) regulatory pathway, potentially enabling a streamlined development timeline.
“Momentum at the national level around psychedelic therapeutics reflects what the science has been signaling for years—there is a critical need for new approaches to treating mental health conditions,” said Eric Weisblum, CEO of Silo Pharma. “We believe Silo is well positioned with SPC-15 and it broader CNS pipeline to potentially benefit from a more favorable regulatory and clinical environment.”
Key Highlights of SPC-15 (PTSD Program):
- Designed as a novel serotonin 4 (5-HT4) receptor agonist
- Targeting prophylactic treatment of PTSD and stress-induced disorders
- Administered via an intranasal formulation designed for rapid CNS delivery
- Backed by intellectual property licensed from Columbia University
- Preparing for IND engagement with the FDA
- Advanced drug delivery strategy
- Partnership for optimized intranasal device development
- Focus on nose-to-brain delivery platforms, a rapidly emerging segment in CNS therapeutics
Market Opportunity
The global mental health therapeutics market continues to expand, with PTSD alone affecting millions of individuals annually. Openness to psychedelic-assisted and psychedelic-derived therapies may unlock significant new treatment paradigms and commercial opportunities.
Silo Pharma believes that evolving regulatory frameworks could accelerate innovation across the sector, particularly for companies with clinically grounded, delivery-optimized, and IP-backed approaches.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. For more information, please visit silopharma.com.
Forward Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at https://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact
investors@silopharma.com
(800) 705-0120
